Reported Earlier, Astellas' PADCEV In Combination With KEYTRUDA Approved By European Commission, For First-Line Treatment Of Advanced Urothelial Cancer
ASTELLAS PHARMA 0.00%
ASTELLAS PHARMA ALPMY |
|
- First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nearly 40 years1
- European Marketing Authorization based on positive overall survival and progression-free survival results from the global Phase 3 EV-302 trial1
